Delivery Order SPE2DB20D3101-SPE2DB25FRPK2
Award Date
7/7/25
Potential Completion Date
7/8/25
Potential Value
$4.2K
Federal Agency
Defense Logistics Agency
Awardee
Amerisourcebergen Drug Corp
Ultimate Awardee
Not listed
NAICS Category
424210 - Drugs and Druggists' Sundries Merchant Wholesalers
PSC Category
6505 - Drugs And Biologicals
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $2,666.41, is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product. The contract is a firm fixed-price delivery order with an ultimate completion date of April 18, 2025. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a Firm Fixed Price Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, for the supply of HEMABATE 250 MCG/ML AMPULML medical products. The contract has a ceiling value of $3,567.20 and an ultimate completion date of June 11, 2025. It is not designated as a set-aside contract. AmerisourceBergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a ceiling value of $1,656.93 and a performance period through May 28, 2025. The contract is not set-aside and was awarded on May 27, 2025. Amerisourcebergen Drug Corp holds a significant Indefinite...
This is a federal contract award from the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a ceiling value of $1,921.55 and a period of performance through July 8, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation, indicating open competition. Amerisourcebergen Drug Corp holds a...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of HEMABATE 250 MCG/ML AMPULML, a medical product, with a ceiling value of $1,271.85 and a performance period ending on June 27, 2025. The contract is a firm fixed-price delivery order, without a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp...
This federal contract award is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The $1,097.24 firm-fixed-price delivery order was awarded to Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. government. The contract has an ultimate completion date of May 24, 2024 and was awarded on May 23, 2024. It is not set aside for any special designation. Amerisourcebergen, a subsidiary...
This federal contract award is a firm fixed price delivery order (SPE2DB20D1100|SPE2DB24FA8J4) issued by the Defense Logistics Agency (DLA) Troop Support Medical to the prime contractor Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the supply of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a ceiling value of $12,900.22 and a performance period through March 21, 2024. Amerisourcebergen Drug Corp holds an indefinite delivery contract...
This federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp is for the delivery of HEMABATE 250 MCG/ML AMPULML, a pharmaceutical product, with a ceiling value of $23,749.20. The contract is a Firm Fixed Price Delivery Order with a period of performance through November 29, 2023. AmerisourceBergen, a major pharmaceutical distributor, holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical division to provide a comprehensive...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of HEMABATE 250 MCG/ML AMPULML. The contract has a ceiling value of $1,813.85 and runs through September 27, 2024. It is a firm fixed-price contract, with no set-aside designation. As a key supplier of pharmaceuticals and medical supplies to the U.S. government, AmerisourceBergen has been awarded numerous Indefinite Delivery...
This federal contract award, valued at $7,061.26, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of HEMABATE 250 MCG/ML AMPUL/ML, a pharmaceutical product, with a completion date of January 23, 2024. Amerisourcebergen is a major supplier of pharmaceutical products and medical supplies to the U.S. federal government, including the Department of Defense (DoD) and Veterans Affairs...